CanBas Co.
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, CanBas Co. sits in the upper quartile of US sponsors by registered trial count (#2,411 of 15,742 sponsors by registered trial count).
CanBas Co.: 5 sponsored US clinical trials, none currently recruiting.
CanBas Co. sponsors 5 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 5 completed. 0 of these trials are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Solid Tumors, with 1 trials.
Upper-quartile sponsor footprint
CanBas Co. sits in the upper quartile of the sponsor corpus (#2,411 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Indexed trials (enrollment closed)
5 total, page 1 of 1
Study of CBP501/Cisplatin/Nivolumab Combinations in Advanced Pancreatic Cancer
NCT04953962
CBP501, Cisplatin and Nivolumab in Advanced Refractory Tumors
NCT03113188
Triplet Combination First Line Treatment in Non Small Cell Lung Cancer (NSCLC)
NCT00942825
Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II)
NCT00700336
Phase I Study of CBP501 and Cisplatin in Patients With Advanced Refractory Solid Tumors
NCT00551512
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 2 |
Therapeutic Areas
How the CanBas Co. early-phase archive is shaped
5 indexed studies, none listed as recruiting (0% open); 5 completed (100%).
Phase mix: 0 late (III/IV) vs 5 early (I/II) (early-phase heavy).
Top condition: Solid Tumors (1 trial), 1 other listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
CanBas Co.: archived-pipeline peers nationwide
Peers matched on 5 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
CanBas Co. sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 5 archived trials
- 4YouandMe · 5 trials · 0% recruiting
- Abbott Rapid Dx · 5 trials · 0% recruiting
- Access Business Group · 5 trials · 0% recruiting
- Acera Surgical · 5 trials · 20% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this CanBas Co. page
5 registered trials is a research-attention snapshot, not an endorsement of CanBas Co. or any single study.
- None of CanBas Co.'s trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Solid Tumors is the condition CanBas Co. studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Solid Tumors trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
CanBas Co. pipeline card: 5 registered trials from official public datasets.Report a data error.